Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (US20070021504) Composition and/or method for preventing onset and/or recurrence of cardiovascular events

Office : United States of America
Application Number: 11481956 Application Date: 07.07.2006
Publication Number: 20070021504 Publication Date: 25.01.2007
Grant Number: 08367725 Grant Date: 05.02.2013
Publication Kind : B2
IPC:
A61K 31/232
A61P 9/10
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
21
Esters, e.g. nitroglycerine, selenocyanates
215
of carboxylic acids
22
of acyclic acids, e.g. pravastatin
23
of acids having a carboxyl group bound to a chain of seven or more carbon atoms
232
having three or more double bonds, e.g. etretinate
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
10
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applicants: Mochida Pharmaceutical Co., Ltd.
Inventors: Yokoyama Mitsuhiro
Origasa Hideki
Matsuzaki Masunori
Matsuzawa Yuji
Saito Yasushi
Ishikawa Yuichi
Oikawa Shinichi
Sasaki Jun
Hishida Hitoshi
Itakura Hiroshige
Kita Toru
Kitabatake Akira
Nakaya Noriaki
Sakata Toshiie
Shimada Kazuyuki
Shirato Kunio
Agents: Birch, Stewart, Kolasch & Birch, LLP
Priority Data: 2005-200503 08.07.2005 JP
Title: (EN) Composition and/or method for preventing onset and/or recurrence of cardiovascular events
Abstract:
(EN)

Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI.


Also published as:
NO20065384EP1790339BRPI0613704-0JP2007039452JP2008050367JP2012193211
US20130065956CN101217952CN102526733CA2570763ES2489741KR1020130137055
US20160045469WO/2007/007686